C Diff Foundation, the Leading Global Patient and Healthcare Organization Educating and Advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) Prevention, Treatments, Clinical trials, Diagnostics, Support, and Environmental Safety.
Intended Audience: Healthcare Professionals
9th Annual International C. diff. LIVE-ONLINE, Two-Day Conference & Health EXPO
November 4-5, 2021 from 10:00 a.m. – 4:00 p.m. EDT #cdiff2021
Complimentary Registration Is Open!
Sometimes in life, events occur that fracture the very foundation on which we stand. Our life, as we have known it, is forever changed and we find ourselves in an unexpected struggle, first just to survive and then to move forward.
C. diff. Survivors unite on November 1st for the first ever live-online meeting
1:00 – 3:00 p.m. ET. Registration is complimentary and we look forward to seeing you online!
This Live-Online meeting is sponsored by Seres Therapeutics
As we continue to attend, and enjoy the many events taking place across the globe, we also encourage everyone to maintain and observe the guidelines being shared by Federal agencies to safely resume enjoying community festivities during these difficult times caused by the COVID-19 global pandemic and its variants. Learn more about the vaccines available: The
C Diff Foundation effectively adapts and overcomes the many obstacles directly related to the virus. Above all, maintaining the safety and well-being of all attendees, visitors, exhibitors, sponsors, and guest speakers — is our top priority. We look forward to meeting you online, and n-person if possible, at all of the scheduled events, and we look forward to seeing you in person during 2021 and remain hopeful for 2022! Thank you for your participation and continued support!
Download C diff and You today to find easy to understand information about
C. diff. (Clostridioides difficile, C. difficile, CDI)
infection prevention, treatments, clinical trials, support, nutrition, diagnostics, environmental safety, and more. Gain the knowledge and grow in advocacy by placing the C. diff. Community in the palm of your hands. Available On the Apple Store and Google Play.
Clostridioides difficile (formally called Clostridium difficile) is gram-positive, anaerobic, and a spore, rod/spindle-shape,
a common bacterium of the human intestine
in 2 – 5%. C diff. becomes a serious gastrointestinal infection when individuals have been exposed to antibiotic therapy, and/or have experienced a long-term hospitalization, and/or have had an extended stay in a long-term care facility. However; the risk of acquiring a C. diff. infection (CDI) has increased as it is in the community and found in outpatient settings. There are significant risk factors in patients who are immunosuppressed individuals who have been on antibiotic therapy and the elderly population.
A C. diff. infection (CDI) is an individual infection and no two individuals will present with the same initial symptoms except for the common denominator of unformed, liquid diarrhea and with more than three times within 24 hours before seeking a stool test to confirm the diagnosis. Each individual will have different courses of treatment and the infection may resolve quickly or there may be episodes of recurrent C. difficile which will require additional courses of treatment. Physicians (Primary Care, Gastroenterologist, Infectious Disease) will determine the course of treatment based on the patient’s symptoms, infection, and age, if there are additional illnesses to consider, a discussion of treatments with the patient will develop a plan of care.
How do Antibiotics cause C. diff.? The antibiotics cause a disruption in the normal intestinal flora which leads to an overgrowth of C. difficile bacteria in the colon. Leading antibiotics are known to disrupt the normal intestinal flora.
As far back as November 2012, the CDC started sharing a public announcement regarding antibiotic use: Colds and many ears and sinus infections are caused by viruses, not bacteria. Taking antibiotics to treat a “virus” can make those drugs less effective when you and your family really need them. Limiting the usage of antibiotics will also help limit new cases of CDI.
*Always discuss the symptoms and medications with the treating Physician/Healthcare Provider.
Contact Us Today
Triage Nurses are available on Tele-Support
Monday through Friday at 9:00 a.m. ET – 4:00 p.m. EST (Not available on Weekends or Holidays) to learn more about C. diff. Prevention, Diagnosis Symptoms, and Transmission Treatments, Environmental Safety, and Support Worldwide.
1 – 844 – FOR – CDIF
1 – 844 – 367 – 2343
+1 (727) – 205 – 3922
Sarah Mische, Ph.D. discusses the Who, What, and Why of Clinical Trials; Preventing and Treating C.diff. Infections LISTEN TODAY
Previous studies indicate that C. difficile has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone. The new study found that 1 out of every 5 patients with a healthcare-associated C. difficile infection experienced a recurrence of the infection and 1 out of every 9 patients aged 65 or older with a healthcare-associated
C. difficile infection died within 30 days of diagnosis.** (1)
The epidemiology of C. diff. infections in the UK:
The height of the epidemic of C. diff. infections in the UK were towards the end of the last decade. There are comprehensive UK data on CDI because of a mandatory reporting system that was introduced over 10 years ago; in England, there were ~60 000 cases in 2007-08, with large, hospital-based outbreaks, some of which led to multiple official reviews of healthcare practice. Major government-led public health campaigns followed, which included the use of targets for every NHS hospital, financial penalties if targets were missed, and (in 2012) standardized testing for CDI across the NHS. These interventions led to an 80% reduction in CDI rates and in CDI-associated mortality; in England, there
were ~14 000 cases in 2013-14. There was a small rise in CDI’s (~6% in 2014-15), which is unexplained. CDI remains a key performance management condition in the NHS, and so low rates are considered as a marker of high-quality healthcare. (2)
There is validation enough for the C Diff Foundation to continue its’ dedication to lowering morbidity and mortality rates through continued education, advocating, and sharing the C Diff Foundation mission in raising C. diff. Awareness with healthcare professionals, healthcare students, healthcare facilities, patients, families, and communities – working towards a shared goal ~ To witness a reduction of newly diagnosed C. diff. cases on a global level — by 2030.
The C Diff Foundation works closely within the healthcare industry and communities, from villages to cities. With the C Diff Foundation Members and their global Volunteer Health Advocates, we successfully “Raise C. diff. Awareness” and have touched lives in fifty-six countries. Working with patients, their families, and within the healthcare community addressing the problems and discussing solutions focused on C. difficile infections is making a difference. “International Raising C.diff. Awareness” takes place through Summits, Symposiums, Workshops, and Annual Conferences each year. The first annual “International Raising C Diff Awareness” Conference was held in November 2013 which brought together some of the best minds in epidemiology and healthcare with new ideas regarding the challenges the world is facing in C.diff. infection prevention, treatments, clinical trials, and environmental safety. By and through presenting specific, scientific data to meet C. diff. challenges, encouraging healthcare professionals, healthcare organizations, and pharmaceutical organizations to share the information and providing scientific data being utilized to implement C. diff. infection solutions.
“Our Foundation is without borders as our outreach expands over horizons dedicated in our mission; Educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide to end the suffering from this infection and help save lives.” states
Nancy C. Caralla, Founding President, Executive Director
(2) Dr. Mark Wilcox, MD, FRCPath, Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, and is the lead on Clostridium difficile for Public Health England in the UK, C Diff Foundation: Chairperson, Medical Advisory Board.
JOIN US and Share Our Mission To Save Lives Worldwide!
* If you are, or you know someone who is, experiencing
symptoms of a C. difficile infection, please contact a physician and seek medical attention immediately.
UPDATE:: Clostridioides difficile is also known as C.difficile, C. diff, CDI (Clostridioides difficile infection), CDAD (Clostridioides difficile-associated disease), and formally called Clostridium difficile.
Please Read Disclaimer Thank you. *
Copyright © 2021 C Diff Foundation – All Rights Reserved